Akebia Therapeutics
AKBA
$1.32
Share price
-1.12%
Change (1 day)
45.60%
Change (1 year)
Categories
Akebia Therapeutics (AKBA) - P/B ratio
P/B ratio as of April 2024 : -9.17
According to Akebia Therapeutics's latest financial reports the company has a price-to-book ratio of -9.17.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Akebia Therapeutics - P/B ratio (from 2014 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | -7.64 | -137.63% |
| 2022-12-31 | 20.3 | 279.87% |
| 2021-12-31 | 5.34 | 226.9% |
| 2020-12-31 | 1.63 | -16.1% |
| 2019-12-31 | 1.95 | 91.65% |
| 2018-12-31 | 1.02 | -82.27% |
| 2017-12-31 | 5.73 | -2.09% |
| 2016-12-31 | 5.86 | 93.66% |
| 2015-12-31 | 3.02 | 32.74% |
| 2014-12-31 | 2.28 | |
| 2013-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.12 | -155.82% | 🇺🇸 USA |
 Novartis NVS | 5.03 | -154.87% | 🇨🇭 Switzerland |
 Amgen AMGN | 23.2 | -353.31% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | 1.85 | -120.17% | 🇺🇸 USA |